Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Add-on, switch-to PEG-IFN therapy strategies improve serological response in CHB patients
Chronic hepatitis B (CHB) patients, who have virological response with long-term entecavir (ETV) treatment, appear to fare well with a strategy of adding or switching to peginterferon (PEG-IFN) therapy, as shown in a study.
Add-on, switch-to PEG-IFN therapy strategies improve serological response in CHB patients
30 Sep 2022
SGLT2 inhibitors potentially protective against dry eye disease
Type 2 diabetes (T2D) patients on sodium-glucose cotransporter 2 (SGLT2) inhibitors appear to be at lower risk of dry eye disease (DED) compared with their counterparts who are receiving glucagonlike peptide-1 receptor agonists (GLP-1 RAs), as shown in a study.
SGLT2 inhibitors potentially protective against dry eye disease
29 Sep 2022
Apixaban better than enoxaparin for extended-duration VTE prophylaxis after surgery
Apixaban is not inferior to enoxaparin for extended-duration venous thromboembolic event (VTE) prophylaxis (EP) following urologic oncology surgery, reveals a study. In addition, apixaban is associated with fewer major complications and compliance-related adverse events.
Apixaban better than enoxaparin for extended-duration VTE prophylaxis after surgery
29 Sep 2022
Adjuvant pembrolizumab continues to improve DFS in clear cell RCC
In patients with clear cell renal cell carcinoma (RCC), adjuvant pembrolizumab continues to improve disease-free survival (DFS) over placebo, according to extended follow-up of the phase III KEYNOTE-564 trial.
Adjuvant pembrolizumab continues to improve DFS in clear cell RCC
28 Sep 2022
FINLAY-FR-1A vaccine boosts natural immunity in COVID-19 convalescents
A single dose of FINLAY-FR-1A, a recombinant d-RBD*-based COVID-19 vaccine, strengthens pre-existing natural immunity in patients who have recovered from asymptomatic, mild or moderate COVID-19, and has an excellent safety profile, a phase IIa/b study has shown.
